Villemagne VL - Search Results

1

The amyloid-β pathway in Alzheimer's disease: a plain language summary.

Hampel H, Hu Y, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A. Hampel H, et al. Among authors: villemagne vl. Neurodegener Dis Manag. 2023 Jun;13(3):141-149. doi: 10.2217/nmt-2022-0037. Epub 2023 Mar 30. Neurodegener Dis Manag. 2023. PMID: 36994753 Free PMC article. Review.

2

Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease.

Villemagne VL, Rowe CC, Macfarlane S, Novakovic KE, Masters CL. Villemagne VL, et al. J Clin Neurosci. 2005 Apr;12(3):221-30. doi: 10.1016/j.jocn.2004.03.011. J Clin Neurosci. 2005. PMID: 15851069 Review.

3

Rare genetically defined causes of dementia.

Novakovic KE, Villemagne VL, Rowe CC, Masters CL. Novakovic KE, et al. Among authors: villemagne vl. Int Psychogeriatr. 2005;17 Suppl 1:S149-94. doi: 10.1017/s1041610205002012. Int Psychogeriatr. 2005. PMID: 16240489 Review.

4

Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease.

Opazo C, Luza S, Villemagne VL, Volitakis I, Rowe C, Barnham KJ, Strozyk D, Masters CL, Cherny RA, Bush AI. Opazo C, et al. Among authors: villemagne vl. Aging Cell. 2006 Feb;5(1):69-79. doi: 10.1111/j.1474-9726.2006.00196.x. Aging Cell. 2006. PMID: 16441845 Free article.

5

Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.

Masters CL, Cappai R, Barnham KJ, Villemagne VL. Masters CL, et al. Among authors: villemagne vl. J Neurochem. 2006 Jun;97(6):1700-25. doi: 10.1111/j.1471-4159.2006.03989.x. J Neurochem. 2006. PMID: 16805778 Free article. Review.

6

Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B.

Ng SY, Villemagne VL, Masters CL, Rowe CC. Ng SY, et al. Among authors: villemagne vl. Arch Neurol. 2007 Aug;64(8):1140-4. doi: 10.1001/archneur.64.8.1140. Arch Neurol. 2007. PMID: 17698704

7

Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.

Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC. Pike KE, et al. Among authors: villemagne vl. Brain. 2007 Nov;130(Pt 11):2837-44. doi: 10.1093/brain/awm238. Epub 2007 Oct 10. Brain. 2007. PMID: 17928318

8

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.

Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL. Rowe CC, et al. Among authors: villemagne vl. Lancet Neurol. 2008 Feb;7(2):129-35. doi: 10.1016/S1474-4422(08)70001-2. Epub 2008 Jan 10. Lancet Neurol. 2008. PMID: 18191617

9

The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.

Villemagne VL, Fodero-Tavoletti MT, Pike KE, Cappai R, Masters CL, Rowe CC. Villemagne VL, et al. Mol Neurobiol. 2008 Aug;38(1):1-15. doi: 10.1007/s12035-008-8019-y. Epub 2008 Aug 9. Mol Neurobiol. 2008. PMID: 18690556 Review.

10

Characterization of PiB binding to white matter in Alzheimer disease and other dementias.

Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li QX, Masters CL, Cappai R, Villemagne VL. Fodero-Tavoletti MT, et al. Among authors: villemagne vl. J Nucl Med. 2009 Feb;50(2):198-204. doi: 10.2967/jnumed.108.057984. Epub 2009 Jan 21. J Nucl Med. 2009. PMID: 19164220 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

413 results

Search Page